JEMPERLI, generically known as dostarlimab, is a cutting-edge immunotherapy medication designed for the treatment of certain types of cancer. It belongs to a class of drugs known as checkpoint inhibitors, specifically targeting the PD-1/PD-L1 pathway, a mechanism that cancer cells exploit to evade the immune system. By inhibiting this pathway, JEMPERLI enhances the body's immune response against cancer cells, offering a promising treatment option for patients with specific indications such as endometrial cancer that is mismatch repair deficient (dMMR) or has high microsatellite instability (MSI-H) after prior treatment failure. Its approval and use mark significant progress in the field of oncology, providing new hope for patients with these challenging conditions.